A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Eric Pujade-Lauraine,Keiichi Fujiwara,Jonathan A. Ledermann,Amit M. Oza,Rebecca Kristeleit,Isabelle Ray-Coquard,Gary Richardson,Cristiana Sessa,Kan Yonemori,Susana Banerjee,Alexandra Leary,Anna V. Tinker,Kyung Hae Jung,Radoslaw Madry,Sang Yoon Park,Charles K. Anderson,Fabian Zohren,Ross A. Stewart,Caimiao Wei,Samuel S. Dychter,Bradley J. Monk +20 more
TL;DR: The JAVELIN Ovarian 200 trial as discussed by the authors showed that avelumab alone or avelummab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer.
Journal ArticleDOI
Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
Laurie Elit,Thomas K. Oliver,Allan Covens,Janice S. Kwon,Michael Fung-Kee Fung,H. Hirte,Amit M. Oza +6 more
TL;DR: The results from this review indicated that cisplatin‐containing intraperitoneal chemotherapy should be offered to patients on the basis of significant improvements in overall survival, and specific aspects of the treatment, such as optimal agent, dose, and scheduling are needed.
Journal ArticleDOI
Treatment strategies for endometrial cancer: current practice and perspective.
TL;DR: The precise role and sequence of conventional and targeted therapies, including immunotherapy, will require careful attention to the design of clinical trials with translational emphasis to allow the discovery, validation, and implementation of predictive biomarkers into clinical care.
Journal ArticleDOI
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Joo Ern Ang,Charlie Gourley,C. Bethan Powell,Hilda High,Ronnie Shapira-Frommer,Vincent Castonguay,Jacques De Greve,T. Atkinson,Timothy A. Yap,Shahneen Sandhu,Susana Banerjee,Lee-may Chen,Michael Friedlander,Bella Kaufman,Amit M. Oza,Ursula A. Matulonis,Louise J. Barber,Iwanka Kozarewa,Kerry Fenwick,Ioannis Assiotis,James Campbell,Lina Chen,Johann S. de Bono,Martin Gore,Christopher J. Lord,Alan Ashworth,Stan B. Kaye +26 more
TL;DR: Heavily pretreated patients with BRCA1/2 mutation carrier ovarian cancer who are PARPi-resistant retain the potential to respond to subsequent chemotherapy, including platinum-based agents, according to a retrospective review of PBMCOC.
Journal ArticleDOI
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen Mackay,Hal W. Hirte,Terrence Colgan,Al Covens,K. MacAlpine,Pamela Grenci,Lisa Wang,Jaqueline Mason,Pnu-An Pham,Ming-S. Tsao,James Pan,James A. Zwiebel,Amit M. Oza +12 more
TL;DR: Belinostat is well tolerated in both patient groups and shows some activity in patients with micropapillary (LMP) disease.